Vysis UroVysion for the detection of urothelial carcinoma.
For decades, cystoscopy and urine cytology have been the mainstay for monitoring superficial urothelial carcinoma patients for tumor recurrence. However, urine cytology has poor sensitivity for urothelial carcinoma and, consequently, numerous investigators have been endeavoring to develop more sensitive assays for the detection of urothelial carcinoma. This article presents an overview of the types of new assays that have been developed for urothelial carcinoma detection but focuses primarily on the features and performance of a new fluorescence in situ hybridization assay for urothelial carcinoma detection known as Vysis UroVysion.
Halling
Kevin C
KC
Mayo Clinic and Foundation, Department of Laboratory Medicine and Pathology, Rochester, MN 55905, USA. halling.kevin@mayo.edu
D002277:Carcinoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D009367:Neoplasm Staging; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology*; D014556:Urine / Q000166:cytology; D019459:Urothelium / Q000473:pathology*